

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06979596

Status	RECRUITING
Phase	Phase 2
Sponsor	Merck Sharp & Dohme LLC
Enrollment	250 participants

Key Eligibility Criteria

Inclusion (14)

- Cohort A:
 - Has a diagnosis of hormone receptor positive/Human Epidermal Growth Factor Receptor 2 negative (HR+/HER2-) invasive breast carcinoma that is either locally advanced disease not amenable to resection with curative intent (herein called unresectable) or metastatic disease not treatable with curative intent.
 - Has experienced disease progression on or after at least 1 prior endocrine-based therapy in the metastatic setting.
 - Cohort B:
 - Has histologically confirmed high-grade epithelial (including high-grade serous or predominantly serous, high-grade endometrioid, malignant mixed Müllerian tumors [carcinosarcoma], or clear cell) ovarian, fallopian tube, or primary peritoneal carcinoma.
- ... and 9 more (see full listing online)

Exclusion (20)

- Cohort A:
 - Breast cancer amenable to treatment with curative intent.
 - Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications, such as lymphangitic lung metastases, radiographic evidence of intratumoral cavitation or invasion/infiltration of a major blood vessel, bone marrow replacement, carcinomatous meningitis, significant symptomatic liver metastases, symptomatic pericardial effusion, symptomatic peritoneal carcinomatosis, or the need to achieve rapid symptom control.
 - Cohort B:
 - Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), borderline tumors (low malignant potential), mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor, low-grade serous, low-grade endometrioid, and undifferentiated carcinoma.
- ... and 15 more (see full listing online)

Locations (49 total)

Alaska Womens Cancer Care (Site 0037), Anchorage, Alaska, United States
Mount Sinai Cancer Center (Site 0009), Miami Beach, Florida, United States
TRIALS 365 (Site 0022), Shreveport, Louisiana, United States
... and 46 more locations